In accordance with these findings, in AIS patients, the elevation of cTnT may be more sensitive to predict unfavorable outcomes as opposed to cTnI.29 A recent meta‐analysis showed that both cTnT and cTnI at baseline can independently predict an increased risk of all‐cause mortality in AIS patients, while efficacy of these predictors was not examined.37 Further studies need to be performed comparing these markers in AIS patients. This evidence concerns the gene TNNT2 and androgen insensitivity syndrome.